Bicara Therapeutics (BCAX) Stock Forecast & Price Target

$23.43 -1.40 (-5.64%)

As of 08/28/2026 04:00 PM Eastern

Compare

Bicara Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 15 Analyst Ratings

Sell
1

Hold
3

Buy
11

Based on 15 Wall Street analysts who have issued ratings for Bicara Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 1 has given a sell rating, 3 have given a hold rating, 9 have given a buy rating, and 2 have given a strong buy rating for BCAX.

Consensus Price Target

$32.64
39.29% Upside

According to the 15 analysts' twelve-month price targets for Bicara Therapeutics, the average price target is $32.64. The highest price target for BCAX is $42.00, while the lowest price target for BCAX is $20.00. The average price target represents a forecasted upside of 39.29% from the current price of $23.43.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for BCAX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Bicara Therapeutics and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BCAX Analyst Ratings Over Time

Type	Current Forecast 8/30/25 to 8/30/26	1 Month Ago 7/31/25 to 7/31/26	3 Months Ago 6/1/25 to 6/1/26	1 Year Ago 8/30/24 to 8/30/25
Strong Buy	2 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	9 Buy rating(s)	10 Buy rating(s)	10 Buy rating(s)	7 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$32.64	$30.27	$30.27	$32.25
Forecasted Upside	39.29% Upside	11.71% Upside	46.81% Upside	170.11% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

BCAX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BCAX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Bicara Therapeutics Stock vs. The Competition

Type	Bicara Therapeutics	Healthcare Companies	Broader Market
Consensus Rating Score	2.80	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	39.29% Upside	841.59% Upside	13.05% Upside
News Sentiment Rating	Positive News See Recent BCAX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/21/2026	Citigroup 4 of 5 stars		Reiterated Rating	Market Outperform
8/18/2026	BMO Capital Markets 3 of 5 stars	David Lebowitz Not Rated	Initiated Coverage	Outperform	$35.00	+40.45%
8/12/2026	Wedbush 5 of 5 stars	David Nierengarten 5 of 5 stars	Boost Target	Outperform	$30.00 ➝ $33.00	+38.89%
8/12/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Catanzaro Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$18.00 ➝ $20.00	-15.82%
8/12/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Law Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$18.00 ➝ $20.00	-15.82%
8/12/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eva Fortea Verdejo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$16.00 ➝ $23.00	-3.20%
8/12/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeet Mukherjee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$28.00 ➝ $39.00	+64.14%
8/11/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Judah Frommer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$37.00 ➝ $39.00	+64.14%
7/6/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell (D-)
5/27/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight
Bezos… DOOMED (Ad) A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25. Watch James Altucher's free video breakdown before the September 25 deadline.
5/11/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brad Canino Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$42.00	+86.01%
3/31/2026	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reni J. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Outperform	$31.00	+62.82%
3/31/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robert Burns Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$40.00 ➝ $42.00	+120.59%
3/25/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tazeen Ahmad Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$35.00	+92.73%
1/14/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
8/18/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kelsey Goodwin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Overweight	$36.00	+213.86%
3/27/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$48.00	+261.99%
11/5/2024	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	T. Butler Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
10/8/2024	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	T. Van. Buren Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:34 AM ET.

BCAX Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Bicara Therapeutics is $32.64, with a high forecast of $42.00 and a low forecast of $20.00.

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bicara Therapeutics in the last year. There is currently 1 sell rating, 3 hold ratings, 9 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BCAX shares.

According to analysts, Bicara Therapeutics's stock has a predicted upside of 39.29% based on their 12-month stock forecasts.

Over the previous 90 days, Bicara Therapeutics's stock had 1 upgrade by analysts.

Bicara Therapeutics has been rated by research analysts at BMO Capital Markets, BTIG Research, Citigroup, Mizuho, Morgan Stanley, The Goldman Sachs Group, Wedbush, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Bicara Therapeutics more than other "healthcare" companies. The consensus rating for Bicara Therapeutics is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how BCAX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Bicara Therapeutics Recommendations

MarketBeat monitors more than a dozen sources for Bicara Therapeutics analyst ratings, with the most recent rating issued on 8/21/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bicara Therapeutics (BCAX) Stock Forecast & Price Target

Bicara Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

BCAX Analyst Ratings Over Time

BCAX Analyst Recommendations By Month

BCAX Price Targets by Month

Bicara Therapeutics Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

BCAX Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Bicara Therapeutics Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bicara Therapeutics (BCAX) Stock Forecast & Price Target

Bicara Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

BCAX Analyst Ratings Over Time

BCAX Analyst Recommendations By Month

BCAX Price Targets by Month

Bicara Therapeutics Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

BCAX Forecast - Frequently Asked Questions

What is Bicara Therapeutics' forecast for 2026?

Should I buy or sell Bicara Therapeutics stock right now?

Does Bicara Therapeutics's stock price have much upside?

Has Bicara Therapeutics been upgraded by Wall Street analysts recently?

What analysts cover Bicara Therapeutics?

Do Wall Street analysts like Bicara Therapeutics more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Bicara Therapeutics Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools